In the same year, Bourantas and colleagues assessed TNF-α, IL-1α, IL-1β, IL-2, sIL-2R, IL-6, and IL-10 in N = 55 patients with MPNs (N = 10 PV, N = 15 CML, N = 10 PMF, and N = 20 ET) at diagnosis, during follow-up and at the time of blast-phase evolution (which occurred for N = 3 PV and N = 5 PMF), and in 100 control subjects. Here, IL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.